Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Gimeracil

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Gimeracil?

Gimeracil is an investigational drug.

There have been 61 clinical trials for Gimeracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Yonsei University.

There are one hundred and sixteen US patents protecting this investigational drug and nine hundred and forty-seven international patents.

Recent Clinical Trials for Gimeracil
Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction AdenocarcinomaRenJi HospitalPhase 2
A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerShanghai Henlius BiotechPhase 3
SOX-based CRT for Esophageal Cancer.Zhejiang Provincial People’s HospitalPhase 1/Phase 2

See all Gimeracil clinical trials

Clinical Trial Summary for Gimeracil

Top disease conditions for Gimeracil
Top clinical trial sponsors for Gimeracil

See all Gimeracil clinical trials

US Patents for Gimeracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gimeracil   Start Trial Metal-salen complex compound, local anesthetic and antineoplastic drug IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP)   Start Trial
Gimeracil   Start Trial Multimodal silica-based nanoparticles   Start Trial
Gimeracil   Start Trial Device and method for drug evaluation and local treatment Kibur Medical, Inc. (Boston, MA)   Start Trial
Gimeracil   Start Trial Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells STC.UNM (Albuquerque, NM)   Start Trial
Gimeracil   Start Trial Pharmaceutical compositions comprising POH derivatives NeOnc Technologies, inc. (Los Angeles, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gimeracil

Drugname Country Document Number Estimated Expiration Related US Patent
Gimeracil China 103781760 2031-06-13   Start Trial
Gimeracil European Patent Office 2738158 2031-06-13   Start Trial
Gimeracil Japan 2013001646 2031-06-13   Start Trial
Gimeracil Japan 5873656 2031-06-13   Start Trial
Gimeracil Russian Federation 2013156414 2031-06-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.